Junctional adhesion molecule B interferes with angiogenic VEGF/VEGFR2 signaling

FASEB Journal

Volumn 29, Issue 8, 2015, Pages 3411-3425

  Meguenani, Mehdi ^a   Miljkovic Licina, Marijana ^f   Fagiani, Ernesta ^b   Ropraz, Patricia ^f   Hammel, Philippe ^f   Aurrand Lions, Michel ^c,d,e   Adams, Ralf H ^g,h   Christofori, Gerhard ^b   Imhof, Beat A ^a   Garrido Urbani, Sarah ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c INSERM   (France)

^d INSTITUT PAOLI CALMETTES   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

^f CNRS   (France)

^g MAX PLANCK INSTITUTE FOR MOLECULAR BIOMEDICINE   (Germany)

^h UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Aortic ring; Endothelial cells; Tumor angiogenesis

Indexed keywords

ANTIBODY; JUNCTIONAL ADHESION MOLECULE B; JUNCTIONAL ADHESION MOLECULE B ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; CELL ADHESION MOLECULE; JAM2 PROTEIN, MOUSE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A; VEGFR2 PROTEIN, MOUSE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; AORTA; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; EX VIVO STUDY; FEMALE; HEMANGIOMA; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION; VASCULAR RING; ANIMAL; C57BL MOUSE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY; TUMOR CELL LINE;

ANIMALIA; MURINAE; MUS;

ANIMALS; CELL ADHESION MOLECULES; CELL LINE, TUMOR; FEMALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84940116882     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.15-270223     Document Type: Article

References (64)

1. Potente, M., Gerhardt, H., and Carmeliet, P. (2011) Basic and therapeutic aspects of angiogenesis. Cell 146, 873-887
2. Stratman, A. N., and Davis, G. E. (2012) Endothelial cell-pericyte interactions stimulate basement membrane matrix assembly: influence on vascular tube remodeling, maturation, and stabilization. Microsc. Microanal. 18, 68-80
3. Kushner, E. J., and Bautch, V. L. (2013) Building blood vessels in development and disease. Curr. Opin. Hematol. 20, 231-236
4. MacMillan, C. J., Doucette, C. D., Warford, J., Furlong, S. J., Hoskin, D. W., and Easton, A. S. (2014) Murine experimental autoimmune encephalomyelitis is diminished by treatment with the angiogenesis inhibitors B20-4.1.1 and angiostatin (K1-3). PLoS ONE 9, e89770
5. Ausprunk, D. H., and Folkman, J. (1977) Migrationand proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc. Res. 14, 53-65
6. Siekmann, A. F., Affolter, M., and Belting, H. G. (2013) The tip cell concept10yearsafter: new playerstuneinforacommon theme. Exp. Cell Res. 319, 1255-1263
7. Seano, G., Chiaverina, G., Gagliardi, P. A., di Blasio, L., Puliafito, A., Bouvard, C., Sessa, R., Tarone, G., Sorokin, L., Helley, D., Jain, R. K., Serini, G., Bussolino, F., and Primo, L. (2014) Endothelialpodosome rosettes regulate vascular branching in tumour angiogenesis. Nat. Cell Biol. 16, 931-941, 931-938
8. Folkman, J. (2007) Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov. 6, 273-286
9. Carmeliet, P. (2003) Angiogenesis in health and disease. Nat. Med. 9, 653-660
10. Baeriswyl, V., and Christofori, G. (2009) The angiogenic switch in carcinogenesis. Semin. Cancer Biol. 19, 329-337
11. Hanahan, D., and Weinberg, R. A. (2011) Hallmarks of cancer: the next generation. Cell 144, 646-674
12. Kerbel, R. S. (2008) Tumor angiogenesis. N. Engl. J. Med. 358, 2039-2049
13. Ebos, J. M., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., and Kerbel, R. S. (2009) Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239
14. Xu, C. S., Wang, Z. F., Dai, L. M., Chu, S. H., Gong, L. L., Yang, M. H., and Li, Z. Q. (2014) Induction of proline-rich tyrosine kinase 2 activation-mediated C6 glioma cell invasion after anti-vascular endothelial growth factor therapy. J. Transl. Med. 12, 148
15. De Bock, K., Mazzone, M., and Carmeliet, P. (2011) Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat. Rev. Clin. Oncol. 8, 393-404
16. Bergers, G., and Hanahan, D. (2008) Modes of resistance to antiangiogenic therapy. Nat. Rev. Cancer 8, 592-603
17. Rapisarda, A., and Melillo, G. (2012) Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat. Rev. Clin. Oncol. 9, 378-390
18. Ibrahim, N., Yu, Y., Walsh, W. R., and Yang, J. L. (2012) Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review) [review]. Oncol. Rep. 27, 1303-1311
19. Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E., and Hanahan, D. (2003) Benefitsoftargeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287-1295
20. Koh, Y. J., Kim, H. Z., Hwang, S. I., Lee, J. E., Oh, N., Jung, K., Kim, M., Kim, K. E., Kim, H., Lim, N. K., Jeon, C. J., Lee, G. M., Jeon, B. H., Nam, D. H., Sung, H. K., Nagy, A., Yoo, O. J., and Koh, G. Y. (2010) Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 18, 171-184
21. Naik, M. U., Vuppalanchi, D., and Naik, U. P. (2003) Essential role of junctional adhesion molecule-1 in basic fibroblast growth factor-induced endothelial cell migration. Arterioscler. Thromb. Vasc. Biol. 23, 2165-2171
22. Lamagna, C., Hodivala-Dilke, K. M., Imhof, B. A., and Aurrand-Lions, M. (2005) Antibody against junctional adhesion molecule-C inhibits angiogenesis and tumor growth. Cancer Res. 65, 5703-5710
23. Orlova, V. V., Economopoulou, M., Lupu, F., Santoso, S., and Chavakis, T. (2006) Junctional adhesion molecule-C regulates vascular endothelial permeability by modulating VE-cadherin-mediated cell-cell contacts. J. Exp. Med. 203, 2703-2714
24. Weber, C., Fraemohs, L., and Dejana, E. (2007) The role of junctional adhesion molecules in vascular inflammation. Nat. Rev. Immunol. 7, 467-477
25. Palmeri, D., van Zante, A., Huang, C. C., Hemmerich, S., and Rosen, S. D. (2000) Vascular endothelial junction-associated molecule, a novel member of the immunoglobulin superfamily, is localized to intercellular boundaries of endothelial cells. J. Biol. Chem. 275, 19139-19145
26. Liang, T. W., Chiu, H. H., Gurney, A., Sidle, A., Tumas, D. B., Schow, P., Foster, J., Klassen, T., Dennis, K., DeMarco, R. A., Pham, T., Frantz, G., and Fong, S. (2002) Vascular endothelial-junctional adhesion molecule (VE-JAM)/JAM 2 interacts with T, NK, and dendritic cells through JAM 3. J. Immunol. 168, 1618-1626
27. Ludwig, R. J., Zollner, T. M., Santoso, S., Hardt, K., Gille, J., Baatz, H., Johann, P. S., Pfeffer, J., Radeke, H. H., Schön, M. P., Kaufmann, R., Boehncke, W. H., and Podda, M. (2005) Junctional adhesion molecules (JAM)-B and-C contribute to leukocyte extravasation to the skinandmediatecutaneous inflammation. J. Invest. Dermatol. 125, 969-976
28. Doñate, C., Ody, C., McKee, T., Ruault-Jungblut, S., Fischer, N., Ropraz, P., Imhof, B. A., and Matthes, T. (2013) Homing of human B cells to lymphoid organs and B-cell lymphoma engraftment are controlled by cell adhesion molecule JAM-C. Cancer Res. 73, 640-651
29. Arcangeli, M. L., Frontera, V., Bardin, F., Obrados, E., Adams, S., Chabannon, C., Schiff, C., Mancini, S. J., Adams, R. H., and Aurrand-Lions, M. (2011) JAM-B regulates maintenance of hematopoietic stem cells in the bone marrow. Blood 118, 4609-4619
30. Arcangeli, M. L., Frontera, V., Bardin, F., Thomassin, J., Chetaille, B., Adams, S., Adams, R. H., and Aurrand-Lions, M. (2012) The junctional adhesion molecule-B regulates JAM-C-dependent melanoma cell metastasis. FEBS Lett. 586, 4046-4051
31. Sacharidou, A., Koh, W., Stratman, A. N., Mayo, A. M., Fisher, K. E., and Davis, G. E. (2010) Endothelial lumen signaling complexes control 3D matrix-specific tubulogenesis through interdependent Cdc42- and MT1-MMP-mediated events. Blood 115, 5259-5269
32. Reynolds, L. E., Watson, A. R., Baker, M., Jones, T. A., D'Amico, G., Robinson, S. D., Joffre, C., Garrido-Urbani, S., Rodriguez-Manzaneque, J. C., Martino-Echarri, E., Aurrand-Lions, M., Sheer, D., Dagna-Bricarelli, F., Nizetic, D., McCabe, C. J., Turnell, A. S., Kermorgant, S., Imhof, B. A., Adams, R., Fisher, E. M., Tybulewicz, V. L., Hart, I. R., and Hodivala-Dilke, K. M. (2010) Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome. Nature 465, 813-817
33. Garrido-Urbani, S., Jemelin, S., Deffert, C., Carnesecchi, S., Basset, O., Szyndralewiez, C., Heitz, F., Page, P., Montet, X., Michalik, L., Arbiser, J., Rüegg, C., Krause, K. H., and Imhof, B. A. (2011) Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARa mediated mechanism. PLoS ONE 6, e14665
34. Baker, M., Robinson, S. D., Lechertier, T., Barber, P. R., Tavora, B., D'Amico, G., Jones, D. T., Vojnovic, B., and Hodivala-Dilke, K. (2011) Use of the mouse aortic ring assay to study angiogenesis. Nat. Protoc. 7, 89-104
35. Skobe, M., Rockwell, P., Goldstein, N., Vosseler, S., and Fusenig, N. E. (1997) Halting angiogenesis suppresses carcinomacell invasion. Nat. Med. 3, 1222-1227
36. Wong, C. W., Wiedle, G., Ballestrem, C., Wehrle-Haller, B., Etteldorf, S., Bruckner, M., Engelhardt, B., Gisler, R. H., and Imhof, B. A. (2000) PECAM-1/CD31 trans-homophilic binding at the intercellular junctions is independent of its cytoplasmic domain; evidence for heterophilic interaction with integrin alphavbeta3 in Cis. Mol. Biol. Cell 11, 3109-3121
37. Skalli, O., Ropraz, P., Trzeciak, A., Benzonana, G., Gillessen, D., and Gabbiani, G. (1986) A monoclonal antibody against alpha-smooth muscle actin: a new probe for smooth muscle differentiation. J. Cell Biol. 103, 2787-2796
38. Fagiani, E., Lorentz, P., Kopfstein, L., and Christofori, G. (2011) Angiopoietin-1 and -2 exert antagonistic functions in tumor angiogenesis, yet both induce lymphangiogenesis. Cancer Res. 71, 5717-5727
39. Aurrand-Lions, M., Johnson-Leger, C., Pepper, M. S., and Imhof, B. A. (2004) Haemangiomas are formed by cells expressing high levels of alphavbeta3 integrin and lacking acetylated LDL uptake. J. Pathol. 203, 700-709
40. Witte, L., Hicklin, D. J., Zhu, Z., Pytowski, B., Kotanides, H., Rockwell, P., and Böhlen, P. (1998) Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. 17, 155-161
41. Kieran, M. W., Kalluri, R., and Cho, Y. J. (2012) The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring Harb. Perspect. Med. 2, a006593
42. Claesson-Welsh, L., and Welsh, M. (2013) VEGFA and tumour angiogenesis. J. Intern. Med. 273, 114-127
43. Naik, M. U., Caplan, J. L., and Naik, U. P. (2014) Junctional adhesion molecule-A suppresses platelet integrin a IIb b3 signaling by recruiting Csk to the integrin-c-Src complex. Blood 123, 1393-1402
44. Shi, L., Fisslthaler, B., Zippel, N., Fromel, T., Hu, J., Elgheznawy, A., Heide, H., Popp, R, and Fleming, I. (2013) MicroRNA-223 antagonizes angiogenesis by targeting b1 integrin and preventing growth factor signaling in endothelial cells. Circ. Res. 113, 1320-1330
45. Legler, D. F., Wiedle, G., Ross, F. P., and Imhof, B. A (2001) Superactivation of integrin alphavbeta3 by low antagonist concentrations. J. CellSci. 114, 1545-1553
46. Sweeney, P., Karashima, T., Kim, S. J., Kedar, D., Mian, B., Huang, S., Baker, C., Fan, Z., Hicklin, D. J., Pettaway, C. A, and Dinney, C. P. (2002) Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin. Cancer Res. 8, 2714-2724
47. Kodack, D. P., Chung, E., Yamashita, H., Incio, J., Duyverman, A M., Song, Y., Farrar, C. T., Huang, Y., Ager, E., Kamoun, W., Goel, S., Snuderl, M., Lussiez, A., Hiddingh, L., Mahmood, S., Tannous, B. A., Eichler, A. F., Fukumura, D., Engelman, J. A, and Jain, R. K. (2012) Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proc. Natl. Acad. Sci. USA 109, E3119-E3127
48. Hanahan, D. (1985) Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315, 115-122
49. Ribatti, D., and Crivellato, E. (2012) "Sprouting angiogenesis", a reappraisal. Dev. Biol. 372, 157-165
50. Miljkovic-Licina, M., Hammel, P., Garrido-Urbani, S., Lee, B. P., Meguenani, M., Chaabane, C., Bochaton-Piallat, M. L., and Imhof, B. A (2012) Targeting olfactomedin-like 3 inhibits tumor growth by impairing angiogenesis and pericyte coverage. Mol. Cancer Ther. 11, 2588-2599
51. Ludwig, R J., Hardt, K., Hatting, M., Bistrian, R., Diehl, S., Radeke, H. H., Podda, M., Schon, M. P., Kaufmann, R., Henschler, R., Pfeilschifter, J. M., Santoso, S., and Boehncke, W. H. (2009) Junctional adhesion molecule (JAM)-B supports lymphocyte rolling and adhesion through interaction with alpha4beta1 integrin. Immunology 128, 196-205
52. Gerhardt, H., and Betsholtz, C. (2003) Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res. 314, 15-23
53. Morikawa, S., Baluk, P., Kaidoh, T., Haskell, A., Jain, R. K., and McDonald, D. M. (2002) Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol. 160, 985-1000
54. Bussolino, F., Mantovani, A., and Persico, G. (1997) Molecular mechanisms of blood vessel formation. Trends Biochem. Sci. 22, 251-256
55. Fisher, K. E., Sacharidou, A., Stratman, A. N., Mayo, A. M., Fisher, S. B., Mahan, R. D., Davis, M. J., and Davis, G. E. (2009) MT1-MMP- and Cdc42-dependent signaling co-regulate cell invasion and tunnel formation in 3D collagen matrices. J. Cell Sci. 122, 4558-4569
56. Joko, T., Shiraishi, A., Akune, Y., Tokumaru, S., Kobayashi, T., Miyata, K., and Ohashi, Y. (2013) Involvement of P38MAPK in human corneal endothelial cell migration induced by TGF-b (2). Exp. Eye Res. 108, 23-32
57. Tamir, I., Stolpa, J. C., Helgason, C. D., Nakamura, K., Bruhns, P., Daeron, M., and Cambier, J. C. (2000) The RasGAP-binding protein p62dok is a mediator of inhibitory FcgammaRIIB signals in B cells. Immunity 12, 347-358
58. De Gramont, A., Van Cutsem, E., Schmoll, H. J., Tabernero, J., Clarke, S., Moore, M. J., Cunningham, D., Cartwright, T. H., Hecht, J. R., Rivera, F., Im, S. A., Bodoky, G., Salazar, R., Maindrault-Goebel, F., Shacham-Shmueli, E., Bajetta, E., Makrutzki, M., Shang, A., André, T., and Hoff, P. M. (2012) Bevacizumab plus oxaliplatinbased chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol. 13, 1225-1233
59. Kusaba, H., Esaki, T., Kishimoto, J., Uchino, K., Arita, S., Kumagai, H., Mitsugi, K., Akashi, K., and Baba, E. (2013) Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer. Cancer Chemother. Pharmacol. 71, 29-34
60. Casanovas, O., Hicklin, D. J., Bergers, G., and Hanahan, D. (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309
61. Tokuoka, H., Muramatsu, S., Sumi-Ichinose, C., Sakane, H., Kojima, M., Aso, Y., Nomura, T., Metzger, D., and Ichinose, H. (2011) Compensatory regulation of dopamine after ablation of the tyrosine hydroxylase gene in the nigrostriatal projection. J. Biol. Chem. 286, 43549-43558
62. Rubenstein, M., Hollowell, C. M., and Guinan, P. (2011) Effects of BCL-2 suppression by antisense oligonucleotides on additional regulators of apoptosis compensatory change in non-targeted protein expression. In Vivo 25, 725-732
63. Bonner, M. Y., and Arbiser, J. L. (2014) The antioxidant paradox: what are antioxidants and how should they be used in a therapeutic context for cancer. Future Med. Chem. 6, 1413-1422
64. Mochin, M. T., Underwood, K. F., Cooper, B., McLenithan, J. C., Pierce, A. D., Nalvarte, C., Arbiser, J., Karlsson, A. I., Moise, A. R., Moskovitz, J., and Passaniti, A. (2015) Hyperglycemia and redox status regulate RUNX2 DNA-binding and an angiogenic phenotype in endothelial cells. Microvasc. Res. 97, 55-64